Insider Buying: Enovis (NYSE:ENOV) Insider Acquires 5,140 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 5,140 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were bought at an average price of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the transaction, the insider directly owned 61,238 shares of the company’s stock, valued at $1,191,691.48. This represents a 9.16% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Monday, June 15th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was bought at an average price of $20.92 per share, with a total value of $20,920.00.
• On Thursday, June 11th, Oliver Engert acquired 1,200 shares of Enovis stock. The stock was bought at an average cost of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were bought at an average cost of $23.00 per share, for a total transaction of $23,000.00.

Enovis Stock Performance

Shares of ENOV stock traded down $0.82 during trading hours on Friday, reaching $18.58. 1,886,327 shares of the company traded hands, compared to its average volume of 1,200,013. The firm has a 50-day moving average price of $25.50 and a 200 day moving average price of $24.20. The company has a market cap of $1.07 billion, a P/E ratio of -0.96 and a beta of 1.31. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. Enovis Corporation has a 12-month low of $18.52 and a 12-month high of $34.28.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same quarter last year, the business earned $0.79 EPS. The firm’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts predict that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. UBS Group reiterated a “buy” rating and issued a $51.00 price target (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Wells Fargo & Company dropped their price objective on Enovis from $39.00 to $33.00 and set an “overweight” rating for the company in a research note on Wednesday. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Evercore set a $32.00 price target on Enovis in a report on Monday, July 6th. Finally, Canaccord Genuity Group dropped their price target on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, August 17th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Enovis presently has an average rating of “Moderate Buy” and a consensus target price of $40.38.

Institutional Trading of Enovis

Several hedge funds have recently bought and sold shares of ENOV. Arax Advisory Partners bought a new position in shares of Enovis during the 4th quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Allworth Financial LP bought a new stake in shares of Enovis in the second quarter worth about $36,000. Danske Bank A S bought a new stake in shares of Enovis in the third quarter worth about $64,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Enovis in the second quarter worth about $48,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.